ESC Congress 2026 Abstract·Oct 26Cardiovascular–kidney–metabolic risk stratification and cardiorenal outcomes with SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes: a global federated network studyCohort study in peopleSGLT2 inhibitorsPaper